Daxdilimab

达司迪利单抗

Report date: 2022/07/04 19:38:02

Base Information

Drug NameDaxdilimab
Drug Alias Nameanti-ILT7 antibodyVIB-7734MEDI-7734HZN-7734
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-LILRA4Dendritic cells modulators
TargetsLeukocyte immunoglobulin-like receptor subfamily A member 4
Therapy Area/IndicationsAlopecia AreataScleroderma, SystemicLupus Erythematosus, Systemic +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[24] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSbi Biotech Co LtdHorizon Therapeutics PLC
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc
Inactive CompaniesViela Bio Inc
Active IndicationsAlopecia AreataLupus Erythematosus, SystemicMyositis
Inactive IndicationsScleroderma, SystemicLupus Erythematosus, DiscoidLupus Erythematosus, Cutaneous +[8] 

Other Information

ATC CodeN/A
Related LinksN/A